Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a top choice among cheap healthcare stocks to buy heading into 2026, with a consensus Buy rating from all 13 analysts covering the stock. Analysts have assigned a median price target of $110, reflecting an upside potential of around 114%. Kristen Kluska and Kate Dellorusso reiterated Buy ratings with price targets of $123 and $110, respectively. Wells Fargo analyst Derek Archila reduced his price target to $106, while Wolfe Research initiated coverage with an Outperform rating and $75 price target. Soleno focuses on novel therapeutics, including Vykat XR for Prader-Willi syndrome.

Read more at Yahoo Finance: Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026?